102040-03-9

• 常用中文名：土贝母苷甲
• 常用英文名：Tubeimoside I
• CAS号：102040-03-9
• 分子式：C₆₃H₉₈O₂₉
• 分子量：1319.435
• 相关类别： 生物化工 植物提取物
• 发布时间：2018-03-15 08:00:00
• 更新时间：2024-01-02 15:51:45
• 土贝母苷甲(Tubeimoside I)是中药土贝母提取物,已被证明为人类各种癌症的一种有效的抗肿瘤剂。

名称

• 中文名: 土贝母皂甙甲
• 英文名: Tubeimoside A
• 中文别名: 土贝母苷甲; 假贝母; 土贝母皂甙
• 英文别名: TUBEIMOSIDE 1; β-D-Xylopyranosyl-(1->3)-6-deoxy-α-L-mannopyranosyl-(1->2)-1-O-{[(2R,3S,4S,4aR,5aS,8S,9S,9aR,17aR,17bR,19aR,19bS,21aS,25aS,27aR,27bR,29S,29aR,30aR)-3,4,8,9,13,29-hexahydroxy-2-(hydroxymethyl)-1 3,17a,19a,19b,24,24,27b-heptamethyl-11,15-dioxo-3,4,4a,7,8,9,9a,12,13,14,15,17a,18,19,19a,19b,20,21,22,23,24,25,25a,27,27a,27b,28,29,29a,30a-triacontahydro-2H,5aH,11H,17H-piceno[3,4-h]dipyrano[3,2-b:3 ;',2'-e][1,4,7,11]tetraoxacyclohexadecin-21a(; TubeimosideI; TUBELMOSIDEA; TUBEMOSIDE A; TUBEIMOSIDE I (RG); (1S,4S,7S,8S,9R,11S,13S,14S,18S,22S,25S,27R,28S,29S,30R,32R,34R,35S,37R,38R,41R,42R,46S,53S,54R,55R,56R,57S,58R)-7,8,18,28,29,35,55,56,58-Nonahydroxy-30,54-bis(hydroxymethyl)-13,18,37,41,48,48,53,54-o ;ctamethyl-2,16,20-trioxo-3,5,10,12,15,21,24,26,31,33-decaoxadecacyclo[39.9.3.2.2.1.0.0.0.0.0]octapentacont-44-en-57-yl β-D-xylopyranoside; Olean-12-en-28-oicacid,3-[[2-O-[4-O-(4-carboxy-3; α-L-Arabinopyranose, O-β-D-xylopyranosyl-(1->3)-O-6-deoxy-α-L-mannopyranosyl-(1->2)-1-O-[[(2R,3S,4S,4aR,5aS,8S,9S,9aR,17aR,17bR,19aR,19bS,21aS,25aS,27aR,27bR,29S,29aR,30aR)-3,4,4a,5a,8,9,9a ,12,13,14,15,17a,18,19,19a,19b,20,21,22,23,24,25,25a,27,27a,27b,28,29,29a,30a-triacontahydro-3,4,8,9,13,29-hexahydroxy-2-(hydroxymethyl)-13,17a,19a,19b,24,24,27b-heptamethyl-11,15-dioxo-2H,7H,11H,17H- piceno[3,4-h]dipyrano[3,2-b:3',2'-e][1,4,7,1; Lobatoside H; Tubeimoside I

物化性质

• 密度: 1.5±0.1 g/cm3
• 分子式: C₆₃H₉₈O₂₉
• 分子量: 1319.435
• 精确质量: 1318.619385
• PSA: 445.19000
• LogP: 6.38
• 折射率: 1.637
• 储存条件: 室温

生物活性

• 描述: 土贝母苷甲(Tubeimoside I)是中药土贝母提取物,已被证明为人类各种癌症的一种有效的抗肿瘤剂。
• 相关类别:
  信号通路 >> 其他 >> 其他
  研究领域 >> 癌症
  天然产物 >> 萜类化合物和糖苷
• 参考文献:

  [1]. Wang Y, et al. Natural plant extract tubeimoside I promotes apoptosis-mediated cell death in cultured human hepatoma (HepG2) cells. Biol Pharm Bull. 2011;34(6):831-8.

  [2]. Xu Y, et al. Intrinsic apoptotic pathway and G2/M cell cycle arrest involved in tubeimoside I-induced EC109 cell death. Chin J Cancer Res. 2013 Jun;25(3):312-21.

  [3]. Wu Q, et al. Tubeimoside-1 attenuates LPS-induced inflammation in RAW 264.7 macrophages and mouse models. Immunopharmacol Immunotoxicol. 2013 Aug;35(4):514-23.

  [4]. Liu HZ, et al. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways. Mol Med Rep. 2011 Sep-Oct;4(5):985-92.

  [5]. Chen WJ, et al. Tubeimoside-1 induces G2/M phase arrest and apoptosis in SKOV-3 cells through increase of intracellular Ca2+ and caspase-dependent signaling pathways. Int J Oncol. 2012 Feb;40(2):535-43.

安全

• 危害码 (欧洲): Xi

上下游产品

上游产品  0
下游产品  1
503-49-1